<div id=toc></div>

# Table of Contents

- [q-bio.QM](#q-bio.QM) [Total: 5]
- [q-bio.BM](#q-bio.BM) [Total: 1]


<div id='q-bio.QM'></div>

# q-bio.QM [[Back]](#toc)

### [1] [Artificial Intelligence Powered Identification of Potential Antidiabetic Compounds in Ficus religiosa](https://arxiv.org/abs/2510.19867)
*Md Ashad Alam,Md Amanullah*

Main category: q-bio.QM

TL;DR: 利用人工智能和计算方法研究榕树植物中的生物活性化合物，发现黄酮类和生物碱类化合物具有显著的抗糖尿病潜力，特别是对DPP-4酶的良好结合作用。


<details>
  <summary>Details</summary>
Motivation: 糖尿病是一种慢性代谢疾病，需要新的治疗创新。榕树作为传统药用植物，其生物活性化合物具有潜在抗糖尿病特性，值得深入研究。

Method: 采用基于生态系统的计算方法，结合机器学习、分子对接技术和ADMET预测系统，评估榕树植物化合物对DPP-4酶的抗糖尿病效果。使用DeepBindGCN和AutoDock软件进行结合相互作用分析。

Result: 研究发现黄酮类和生物碱类化合物具有强结合相互作用和有利的药理效应。AI加速了筛选过程并提高了准确性。

Conclusion: 该研究为未来实验验证天然产物糖尿病治疗方法提供了科学基础，证明了AI在植物基抗糖尿病药物研究中的有效性。

Abstract: Diabetes mellitus is a chronic metabolic disorder that necessitates novel
therapeutic innovations due to its gradual progression and the onset of various
metabolic complications. Research indicates that Ficus religiosa is a
conventional medicinal plant that generates bioactive phytochemicals with
potential antidiabetic properties. The investigation employs ecosystem-based
computational approaches utilizing artificial intelligence to investigate and
evaluate compounds derived from Ficus religiosa that exhibit antidiabetic
properties. A comprehensive computational procedure incorporated machine
learning methodologies, molecular docking techniques, and ADMET prediction
systems to assess phytochemical efficacy against the significant antidiabetic
enzyme dipeptidyl peptidase-4 (DPP-4). DeepBindGCN and the AutoDock software
facilitated the investigation of binding interactions via deep learning
technology. Flavonoids and alkaloids have emerged as attractive phytochemicals
due to their strong binding interactions and advantageous pharmacological
effects, as indicated by the study. The introduction of AI accelerated
screening procedures and enhanced accuracy rates, demonstrating its efficacy in
researching plant-based antidiabetic agents. The scientific foundation now
facilitates future experimental validation of natural product therapies
tailored for diabetic management.

</details>


### [2] [Transforming Multi-Omics Integration with GANs: Applications in Alzheimer's and Cancer](https://arxiv.org/abs/2510.19870)
*Md Selim Reza,Sabrin Afroz,Mostafizer Rahman,Md Ashad Alam*

Main category: q-bio.QM

TL;DR: Omics-GAN是一个基于生成对抗网络的多组学数据生成框架，能够生成高质量合成多组学数据并保持生物学关系，显著提升疾病预测准确性。


<details>
  <summary>Details</summary>
Motivation: 多组学数据整合对理解复杂疾病至关重要，但样本量有限、噪声和异质性等问题降低了预测能力。

Method: 使用生成对抗网络(GAN)框架生成合成多组学数据，在ROSMAP阿尔茨海默病队列和TCGA结肠癌、肝癌数据集上评估，采用支持向量机分类器和5折交叉验证。

Result: 合成数据显著提升预测准确率：mRNA在AD中AUC从0.72提升至0.74，肝癌中从0.68提升至0.72；miRNA在结肠癌中从0.59提升至0.69；甲基化数据在肝癌中从0.64提升至0.71。

Conclusion: Omics-GAN增强疾病预测能力，保持生物学保真度，加速生物标志物和药物发现，为精准医学提供可扩展策略。

Abstract: Multi-omics data integration is crucial for understanding complex diseases,
yet limited sample sizes, noise, and heterogeneity often reduce predictive
power. To address these challenges, we introduce Omics-GAN, a Generative
Adversarial Network (GAN)-based framework designed to generate high-quality
synthetic multi-omics profiles while preserving biological relationships. We
evaluated Omics-GAN on three omics types (mRNA, miRNA, and DNA methylation)
using the ROSMAP cohort for Alzheimer's disease (AD) and TCGA datasets for
colon and liver cancer. A support vector machine (SVM) classifier with repeated
5-fold cross-validation demonstrated that synthetic datasets consistently
improved prediction accuracy compared to original omics profiles. The AUC of
SVM for mRNA improved from 0.72 to 0.74 in AD, and from 0.68 to 0.72 in liver
cancer. Synthetic miRNA enhanced classification in colon cancer from 0.59 to
0.69, while synthetic methylation data improved performance in liver cancer
from 0.64 to 0.71. Boxplot analyses confirmed that synthetic data preserved
statistical distributions while reducing noise and outliers. Feature selection
identified significant genes overlapping with original datasets and revealed
additional candidates validated by GO and KEGG enrichment analyses. Finally,
molecular docking highlighted potential drug repurposing candidates, including
Nilotinib for AD, Atovaquone for liver cancer, and Tecovirimat for colon
cancer. Omics-GAN enhances disease prediction, preserves biological fidelity,
and accelerates biomarker and drug discovery, offering a scalable strategy for
precision medicine applications.

</details>


### [3] [Advancing Drug Development Through Strategic Cell Line and Compound Selection Using Drug Response Profiles](https://arxiv.org/abs/2510.19874)
*Abbi Abdel-Rehim,Emma Tate,Larisa N. Soldatova,Ross D. King*

Main category: q-bio.QM

TL;DR: 药物反应面板描述符在预测癌症细胞系敏感性方面优于组学数据，能有效识别生物标志物和区分表型，支持早期药物开发。


<details>
  <summary>Details</summary>
Motivation: 早期识别敏感癌症细胞系对加速生物标志物发现和阐明药物作用机制至关重要。小规模药物筛选相对于广泛的组学分析更高效且成本更低。

Method: 使用梯度提升树模型比较药物反应面板描述符与组学特征在GDSC和CCLE药物反应数据集中的预测能力。采用可解释性方法验证已知MAPK抑制剂敏感性特征并识别新生物标志物。

Result: 药物反应面板描述符在关键性能指标上持续优于组学数据，不同药物间表现各异。成功识别了MEK1/2和BTK/MNK抑制剂的新潜在生物标志物，并能有效区分MCF7与MCF10A表型。

Conclusion: 基于聚焦药物和细胞系面板开发的该方法支持早期药物开发，促进合理细胞系选择和化合物优先排序，实现更高效的生物标志物识别和候选评估。

Abstract: Early identification of sensitive cancer cell lines is essential for
accelerating biomarker discovery and elucidating drug mechanism of action.
Given the efficiency and low cost of small-scale drug screens relative to
extensive omics profiling, we compared drug-response panel (DRP) descriptors
against omics features for predictive capacity using gradient boosting tree
models across the GDSC and CCLE drug response datasets. DRP descriptors
consistently outperformed omics data across key performance metrics, with
variable performance across different drugs. Using complementary explainability
approaches, we confirmed known MAPK-inhibitor sensitivity signatures, and
identified novel potential biomarker candidates for MEK1/2 and BTK/MNK
inhibitors. Lastly, to demonstrate the utility of this approach in
distinguishing phenotypes, we applied our models to the breast cancer line MCF7
versus the non-tumorigenic MCF10A, and successfully identified compounds that
selectively inhibit MCF7 while sparing the non-tumorigenic MCF10A. This
methodology, developed using focused drug and cell line panels, supports
early-stage drug development by facilitating rational cell line selection and
compound prioritisation, enabling more efficient biomarker identification and
candidate assessment.

</details>


### [4] [Compressing Biology: Evaluating the Stable Diffusion VAE for Phenotypic Drug Discovery](https://arxiv.org/abs/2510.19887)
*Télio Cropsal,Rocío Mercado*

Main category: q-bio.QM

TL;DR: 本文系统评估了Stable Diffusion的变分自编码器(SD-VAE)在Cell Painting显微镜图像重建中的性能，发现其能有效保留表型信号，并证明通用特征提取器在检索任务中表现优异。


<details>
  <summary>Details</summary>
Motivation: 高通量表型筛选产生的大规模显微镜图像数据集对生成模型提出了挑战，目前尚不清楚基于自然图像训练的通用模型在显微镜数据分析中的适用性。

Method: 使用SD-VAE重建Cell Painting图像，通过像素级、嵌入空间、潜在空间和基于检索的指标系统评估重建质量，并与专用模型进行比较。

Result: SD-VAE重建能最小化损失地保留表型信号；通用特征提取器(如InceptionV3)在检索任务中表现优于或等同于专用模型。

Conclusion: 研究为显微镜数据生成模型评估提供了实用指南，支持在表型药物发现中使用现成的通用模型。

Abstract: High-throughput phenotypic screens generate vast microscopy image datasets
that push the limits of generative models due to their large dimensionality.
Despite the growing popularity of general-purpose models trained on natural
images for microscopy data analysis, their suitability in this domain has not
been quantitatively demonstrated. We present the first systematic evaluation of
Stable Diffusion's variational autoencoder (SD-VAE) for reconstructing Cell
Painting images, assessing performance across a large dataset with diverse
molecular perturbations and cell types. We find that SD-VAE reconstructions
preserve phenotypic signals with minimal loss, supporting its use in microscopy
workflows. To benchmark reconstruction quality, we compare pixel-level,
embedding-based, latent-space, and retrieval-based metrics for a biologically
informed evaluation. We show that general-purpose feature extractors like
InceptionV3 match or surpass publicly available bespoke models in retrieval
tasks, simplifying future pipelines. Our findings offer practical guidelines
for evaluating generative models on microscopy data and support the use of
off-the-shelf models in phenotypic drug discovery.

</details>


### [5] [Drug-disease networks and drug repurposing](https://arxiv.org/abs/2510.19948)
*Austin Polanco,M. E. J. Newman*

Main category: q-bio.QM

TL;DR: 该论文提出了一种基于网络链接预测的药物重定位方法，通过构建药物-疾病关联网络，使用图嵌入和网络模型拟合等技术，显著提高了药物-疾病关联预测性能。


<details>
  <summary>Details</summary>
Motivation: 药物重定位是比从头开发新药更经济有效的方法，但数百万种可能的药物-疾病组合中只有极少数可行。计算预测方法可以大幅缩小搜索空间。

Method: 结合现有文本和机器可读数据库、自然语言处理工具和人工整理，构建药物-疾病治疗网络，使用基于网络的链接预测方法（特别是图嵌入和网络模型拟合）识别潜在药物-疾病组合。

Result: 交叉验证测试显示，多种方法特别是基于图嵌入和网络模型拟合的方法取得了优异的预测性能，ROC曲线下面积超过0.95，平均精度比随机预测高出近千倍。

Conclusion: 网络链接预测方法，特别是图嵌入和网络模型拟合技术，在药物重定位任务中表现出色，显著优于先前方法，为药物重定位提供了有效的计算工具。

Abstract: Repurposing existing drugs to treat new diseases is a cost-effective
alternative to de novo drug development, but there are millions of potential
drug-disease combinations to be considered with only a small fraction being
viable. In silico predictions of drug-disease associations can be invaluable
for reducing the size of the search space. In this work we present a novel
network of drugs and the diseases they treat, compiled using a combination of
existing textual and machine-readable databases, natural-language processing
tools, and hand curation, and analyze it using network-based link prediction
methods to identify potential drug-disease combinations. We measure the
efficacy of these methods using cross-validation tests and find that several
methods, particularly those based on graph embedding and network model fitting,
achieve impressive prediction performance, significantly better than previous
approaches, with area under the ROC curve above 0.95 and average precision
almost a thousand times better than chance.

</details>


<div id='q-bio.BM'></div>

# q-bio.BM [[Back]](#toc)

### [6] [Predicting Protein-Nucleic Acid Flexibility Using Persistent Sheaf Laplacians](https://arxiv.org/abs/2510.20788)
*Nicole Hayes,Ekaterina Merkurjev,Guo-Wei Wei*

Main category: q-bio.BM

TL;DR: 本文提出使用持久层拉普拉斯（PSL）框架预测蛋白质-核酸复合物的B因子，该方法整合多尺度分析、代数拓扑、组合拉普拉斯和层理论，在三个不同数据集上优于传统模型。


<details>
  <summary>Details</summary>
Motivation: 传统模型如高斯网络模型和弹性网络模型在捕捉大分子或复杂生物分子系统的多尺度相互作用方面存在不足，需要更先进的框架来准确预测蛋白质-核酸复合物的灵活性。

Method: 应用持久层拉普拉斯（PSL）框架，该方法整合多尺度分析、代数拓扑、组合拉普拉斯和层理论进行数据表示，通过谐波谱揭示拓扑不变量，通过非谐波谱捕捉数据的同伦形状演化。

Result: 在三个不同数据集（包括蛋白质-RNA和纯核酸结构）上的测试表明，PSL在B因子预测方面始终优于GNM和多尺度FRI模型，皮尔逊相关系数最高提升21%。

Conclusion: PSL在建模复杂生物分子相互作用方面表现出鲁棒性和适应性，在突变影响分析和药物设计等更广泛应用中具有潜在价值。

Abstract: Understanding the flexibility of protein-nucleic acid complexes, often
characterized by atomic B-factors, is essential for elucidating their
structure, dynamics, and functions, such as reactivity and allosteric pathways.
Traditional models such as Gaussian Network Models (GNM) and Elastic Network
Models (ENM) often fall short in capturing multiscale interactions, especially
in large or complex biomolecular systems. In this work, we apply the Persistent
Sheaf Laplacian (PSL) framework for the B-factor prediction of protein-nucleic
acid complexes. The PSL model integrates multiscale analysis, algebraic
topology, combinatoric Laplacians, and sheaf theory for data representation. It
reveals topological invariants in its harmonic spectra and captures the
homotopic shape evolution of data with its non-harmonic spectra. Its
localization enables accurate B-factor predictions. We benchmark our method on
three diverse datasets, including protein-RNA and nucleic-acid-only structures,
and demonstrate that PSL consistently outperforms existing models such as GNM
and multiscale FRI (mFRI), achieving up to a 21% improvement in Pearson
correlation coefficient for B-factor prediction. These results highlight the
robustness and adaptability of PSL in modeling complex biomolecular
interactions and suggest its potential utility in broader applications such as
mutation impact analysis and drug design.

</details>
